Sökning: onr:"swepub:oai:DiVA.org:oru-110308" >
Health-Related Qual...
-
Bergthorsdottir, RSahlgrenska University Hospital, Gothenburg, Sweden
(författare)
Health-Related Quality of Life In Patients With Adrenal Insufficiency Receiving Plenadren Compared With Immediate-Release Hydrocortisone
- Artikel/kapitelEngelska2015
Förlag, utgivningsår, omfång ...
-
Elsevier,2015
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:oru-110308
-
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-110308URI
-
https://doi.org/10.1016/j.jval.2015.09.2145DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-124656URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
BackgroundPrevious studies in patients with primary adrenal insufficiency (PAI) on conventional replacement therapy suggest decreased health-related quality of life (HRQoL), and that patients report more frequently fatigue, increased anxiety and inability to work compared to background population.ObjectivesTo study self-reported health status with EQ-5D in patients with PAI. Patients treated with Plenadren (modified-release hydrocortisone) were compared with patients treated with immediate release hydrocortisone (IRHC) replacement therapy.MethodsThis was a cross-sectional, multi-centre, non-interventional survey of patients with PAI receiving Plenadren or immediate release hydrocortisone (IRHC) replacement.SubjectsOne hundred thirty-four adult patients with PAI of whom 36 (19 females [53%]) were treated with Plenadren and 98 (77 females [79%]) were treated with IRHC, were included.MAIN OUTCOME MEASUREHRQoL described by the EQ-5D, a generic preference-based measure of health.RESULTSPatients on Plenadren and on IRHC had a mean ± SD age of 53.1 ± 12.7 years and 48.0 ± 13.1 years, respectively (P=0.043). The majority of the patients were diagnosed more than 5 years ago (69%). The mean ± SD daily Plenadren and IRHC doses were 27.0 ± 6.8 mg and 26.6 ± 10.9 mg, respectively (P=0.807). 47% of the Plenadren patients had been receiving Plenadren and 82% of the IRHC patients had been receiving IRHC for more than 3 years. Patients receiving Plenadren had better HRQoL measured by the EQ-5D questionnaire compared to patients replaced with IRHC (0.76 ± 0.18 vs 0.68 ± 0.18, respectively [P=0.040]).CONCLUSIONSReplacement therapy with Plenadren in patients with PAI confers measurable benefit on HRQoL relative to IRHC as estimated by the EQ-5D questionnaire, and may therefore be advantageous when compared to IRHC substitution.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Nilsson, A GSahlgrenska University Hospital, Gothenburg, Sweden
(författare)
-
Gillberg, PShire, Danderyd, Sweden
(författare)
-
Ekman, BertilLinköpings universitet,Östergötlands Läns Landsting,Endokrinmedicinska kliniken,Avdelningen för kardiovaskulär medicin,Medicinska fakulteten(Swepub:liu)berek83
(författare)
-
Wahlberg, Jeanette,1969-Linköpings universitet,Östergötlands Läns Landsting,Endokrinmedicinska kliniken,Avdelningen för kardiovaskulär medicin,Medicinska fakulteten(Swepub:liu)jeawa98
(författare)
-
Sahlgrenska University Hospital, Gothenburg, SwedenShire, Danderyd, Sweden
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Value in Health: Elsevier18:71098-30151524-4733
Internetlänk
Hitta via bibliotek
Till lärosätets databas